RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement builds upon Merck’s existing technology collaboration with Certara to aid in regulatory submissions.
Reducing the time from data collection to validated, analysis-ready datasets has become more complex across drug development. Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade.1 The Certara Pinnacle 21 platform is designed to solve the data standardization challenges of modern digital trials at scale.
“We are pleased to strengthen our ongoing collaboration with Merck to assist with data standards management and to expand the value of the Pinnacle 21 platform,” said William F. Feehery, Chief Executive Officer. “Merck is a premier research-intensive company, and our teams are well-aligned in the goal of delivering high-quality research data faster to help save and improve lives around the world.”
To learn more about Pinnacle 21 Enterprise clinical data management and automation suite, please visit www.certara.com/pinnacle-21-enterprise-software/
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.
1 Tufts Center for the Study of Drug Development (CSDD) Impact Report November/December 2021
| Last Trade: | US$11.40 |
| Daily Change: | 0.47 4.30 |
| Daily Volume: | 1,290,651 |
| Market Cap: | US$1.850B |
May 05, 2025 April 14, 2025 April 14, 2025 April 01, 2025 February 26, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
